MedPath

Labor Induction in Preeclampsia High-risk Women

Not Applicable
Recruiting
Conditions
Induction of Labor
Pre-Eclampsia
Interventions
Procedure: Induction of Labor
Registration Number
NCT05056467
Lead Sponsor
Chinese University of Hong Kong
Brief Summary

Preeclampsia (PE) is one of the leading causes of maternal and perinatal morbidity and mortality. This pregnancy-specific disorder poses to both pregnant women and their offspring an increased risk of immediate and long-term health problems. The study team is conducting a study entitled "FORECAST" (Implementation of First-trimester Screening and preventiOn of pREeClAmpSia Trial) and established the infrastructure for the first-trimester "screen and prevent" program for preterm PE. However, there is no established evidence regarding the benefit of scheduled labor induction versus expectant management among women identified as high-risk for PE with uncomplicated pregnancy at term. The investigators postulate that induction of labor at 39 weeks' gestation may possibly be an effective intervention to reduce placental complications in women with uncomplicated pregnancy by 39 weeks at high-risk PE women.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
825
Inclusion Criteria
  • Age no less than 18 years
  • Singleton pregnancy with cephalic presentation and no contraindication to vaginal delivery
  • Live fetus
  • Screened high-risk for PE
  • Informed and written consent
Read More
Exclusion Criteria
  • Multiple pregnancy
  • Pregnant women who plan to have Cesarean delivery
  • Pregnancies complicated by the major fetal abnormality
  • Women who are severely ill, those with learning difficulties, or serious mental illness
  • Pregnant women with medical, obstetric, or fetal complications or any other indications for delivery before 39 weeks' gestation
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
IOLInduction of LaborPreeclampsia High-risk Women schedule labor induction at 39 weeks of gestation
Primary Outcome Measures
NameTimeMethod
the rate of adverse placental outcomesAt Delivery

To compare the difference in the rate of adverse placental outcomes (PE, gestational hypertension (GH), SGA, stillbirth, perinatal death, placental abruption) in the induction of labor group with the expectant management group.

Secondary Outcome Measures
NameTimeMethod
the rate of adverse maternal outcomes6 weeks Postpartum

To compare the difference in the rate of maternal secondary outcomes including composite outcomes of the following: Cesarean delivery/indication for Cesarean delivery, operative vaginal delivery, indication for operative vaginal delivery, uterine incisional extensions during Cesarean delivery, chorioamnionitis, third-degree or fourth-degree perineal laceration, postpartum hemorrhage, postpartum infection, venous thromboembolism, number of hours in the labor and delivery unit, length of postpartum hospital stay, admission to the intensive care unit, and maternal death, between the induction of labor group and the expectant management group.

the rate of adverse neonatal outcomes28 days after birth

To compare the difference in the rate of neonatal secondary outcomes including the composite outcomes of the following: perinatal death or severe neonatal complications and consisted of one or more of the following during the antepartum or intrapartum period or during the delivery hospitalization between the induction of labor group and the expectant management group.

Trial Locations

Locations (8)

Angel Women's and Children's Hospital

🇨🇳

Chengdu, China

Harapan Kita Hospital

🇮🇩

Jakarta, Indonesia

Prince of Wales Hospital

🇭🇰

Hong Kong, Hong Kong

National University Hospital

🇸🇬

Singapore, Singapore

Taiji Clinic

🇨🇳

Taipei, Taiwan

Siriraj Hospital

🇹🇭

Bangkok, Thailand

Hanoi Obstetrics & Gynecology Hospital

🇻🇳

Hanoi, Vietnam

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

🇨🇳

Nanjing, China

© Copyright 2025. All Rights Reserved by MedPath